We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

CDK

CDK inhibitors block cyclin-dependent kinases (CDKs), the serine/threonine kinases that drive the cell cycle. Each CDK becomes active only when bound to a cyclin partner, and successive cyclin-CDK complexes order DNA replication and mitosis. CDK4 and CDK6 pair with D-type cyclins to control progression through G1, while CDK1 governs entry into mitosis. Palbociclib and abemaciclib are selective CDK4/6 inhibitors used to study G1 arrest and retinoblastoma protein phosphorylation. Dinaciclib and seliciclib act on several family members, including CDK2, CDK5 and CDK9, which also links them to transcription research. Ro 3306 inhibits CDK1 and is used to hold cells reversibly at the G2/M boundary for synchronization experiments.

1 Item

  • CDK9 ligand 4
    Cat. No.
    A81329
    CAS No.
    2609749-29-1

    CDK9 ligand 4

    CDK9 ligand 4 functions as a potent ligand for cyclin-dependent kinase 9 (CDK9). This compound is instrumental in the design and development of PROTAC-based degraders, facilitating targeted degradation of CDK9 proteins, which plays a crucial role in transcriptional regulation and HIV-1 infection research. CDK9 ligand 4 contributes significantly to studies aimed at therapeutic strategies against viral infections and dysregulated transcriptional processes.

    View Details

    Out of stock

    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...